Abstract YO8
Case summary
Carcinosarcoma of the breast is an aggressive, malignant biphasic neoplasm. It is comprised of carcinomatous and sarcomatous elements and accounts for 0.08–0.2% of all breast malignancies. Due to the rarity of this disease, it remains poorly understood and infrequently reported. Here we present a case of a 38 year old Filipino woman with a 2 month history of mass in her left breast. Progressive enlargement of the mass warranted excisional biopsy and revealed high grade carcinoma. Metastatic work up were unremarkable. Thus, the patient underwent modified radical mastectomy. Histopathology revealed metaplastic carcinoma, carcinosarcoma type with background of ductal carcinoma in-situ, nuclear grade 1 with no definite lymphovascular space invasion. All 12 lymph nodes were negative for tumor but nipple was positive for tumor. Immunohistochemistry report revealed positive for ER, PR and negative for HER2/Neu overexpression. Furthermore, tumor cells were positive for pancytokeratin in carcinomatous areas and vimentin in sarcomatous areas. The patient is receiving hormonal therapy and remains to be asymptomatic and on close surveillance.
A multi-disciplinary approach with an accurate diagnosis are essential to optimally tailor potentially effective treatment options in this kind of patients. To date, there is no standardized treatment protocol for the management of carcinosarcoma of the breast. Long-term follow-up is important because of the increased likelihood of local recurrence and metastasis.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study
Presenter: Wenbai Huang
Session: Poster display session
Resources:
Abstract
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract